POM-V
Prescription Required
Companion Animal
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
Active ingredient: Butorphanol
Form
Injection
Species
Cats
Dogs
Horses
Manufacturer
V.M.D. n.v.
VMD MA No.
19968/3000
What it's used for
As a sedative: For sedation after the administration of certain alpha2-adrenoceptor agonists (detomidine, romifidine). DOG As an analgesic: For relief of m...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Butorphanol
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
As a sedative: For sedation after the administration of certain alpha2-adrenoceptor
agonists (detomidine, romifidine).
DOG
As an analgesic: For relief of moderate visceral pain.
As a sedative: For sedation in combination with certain alpha2-adrenoceptor agonists
(medetomidine).
As a pre-anaesthetic: For pre-anaesthesia as sole agent and in combination with
acepromazine.
As an anaesthetic: For anaesthesia in combination with medetomidine and ketamine.
CAT
As an analgesic for the relief of moderate pain: For pre-operative analgesia in
combination with acepromazine/ketamine or xylazine/ketamine.
For post- operative analgesia after small surgical procedures.
As a sedative: For sedation in combination with certain alpha2-adrenoceptor agonists
(medetomidine).
As an anaesthetic: For anaesthesia in combination with medetomidine and ketamine.
agonists (detomidine, romifidine).
DOG
As an analgesic: For relief of moderate visceral pain.
As a sedative: For sedation in combination with certain alpha2-adrenoceptor agonists
(medetomidine).
As a pre-anaesthetic: For pre-anaesthesia as sole agent and in combination with
acepromazine.
As an anaesthetic: For anaesthesia in combination with medetomidine and ketamine.
CAT
As an analgesic for the relief of moderate pain: For pre-operative analgesia in
combination with acepromazine/ketamine or xylazine/ketamine.
For post- operative analgesia after small surgical procedures.
As a sedative: For sedation in combination with certain alpha2-adrenoceptor agonists
(medetomidine).
As an anaesthetic: For anaesthesia in combination with medetomidine and ketamine.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
HORSE
For analgesia
Analgesic effects are seen within 15 minutes of injection and last approximately 2
hours.
RouteDose
Butorphanol
mg/kg body
weight
Dose Alvegesic
vet. 10 mg/ml
ml/kg body
weight
CommentIV0.100.01 mlDose may be repeated after 3-4
hours. Treatment should not exceed
48 hours.
For sedation (intravenous use) when used in combination with other drugs
Combination sedation
agent
(given 5 minutes
before Alvegesic vet.
10mg/ml Solution for
Injection)
IV Dose of
Combination
Agent
mg/kg body
weight
IV Dose
Butorphanol
mg/kg body
weight
IV Dose
Alvegesic vet.
10mg/ml
ml/100 kg body
weight
Detomidine
hydrochloride*
0.0120.0250.25 ml / 100 kg bwRomfidine0.04-0.120.020.20 ml / 100 kg bw
* Clinical experience has shown that a total dose rate of 5 mg detomidine
hydrochloride and 10 mg butorphanol affords effective, safe sedation in horses above
200 kg body weight.
DOG
For analgesia
Analgesic effects are seen within 15 minutes post injection.
RouteDose
Butorphanol
mg/kg body
weight
Dose Alvegesic vet.
10 mg/ml
ml/kg body weight
CommentIV,
IM or
SC
0.20-0.300.02-0.03 mlAvoid rapid IV injection (see
section 3.6). Administer 15
minutes before terminating
anaesthesia to provide
analgesia in the recovery phase.
Repeat dose as required.
For sedation when used in combination with other drugs
RouteDose
Butorphanol
mg/kg
body
weight
Dose
Alvegesic
vet
10 mg/ml
ml/kg
body
weight
Dose
Medetomidine
hydrochloride
mg/kg
body weight
CommentIM or0.10.01 ml0.01-0.025Allow 20 minutes for profoundIV(depends onsedation to develop beforedegree ofcommencing the proceduresedationrequired)
For use as a premedicant/pre-anaesthetic
1. when Alvegesic vet 10mg/ml Solution for Injection is used as the sole agent:
Dose
Butorphanol
mg/kg body
weight
Dose
Alvegesic vet 10
mg/ml
ml/kg body
weight
RouteTime of administration0.1-0.200.01-0.02 mlIV, IM or
SC
15 minutes prior to induction
2. when Alvegesic vet 10mg/ml Solution for Injection is used together with 0.02
mg/kg acepromazine:
Dose
Butorphanol
mg/kg body
weight
Dose
Alvegesic vet 10
mg/ml
ml/kg body weight
RouteTime of administration0.10*0.01 ml*IV or IMAllow at least 20 minutes before
the onset of action but the time
between pre-medication and
induction is flexible from 20-120
minutes
The dose may be increased to 0.2 mg/kg (equivalent to 0.02 ml/kg) if the animal
is already experiencing pain before the procedure commences or if a higher
plane of analgesia is required during surgery.
For anaesthesia in combination with medetomidine & ketamine
RouteDose
Butorphanol
mg/kg
body weight
Dose
Alvegesic
vet 10
mg/ml
ml/kg
body
weight
Dose
Medetomidine
mg/kg
body weight
Dose
Ketamine
mg/kg
body
weight
CommentsIM0.100.01 ml0.0255.0*Reversal with
atipamezole is not
recommended
* Ketamine should be administered 15 minutes after IM administration
of the butorphanol/medetomidine combination.
Post IM administration of the combination the veterinary medicinal product
/medetomidine, recumbency and loss of pedal reflex occurs in approximately 6
minutes and 14 minutes, respectively. Post administration of ketamine, the pedal
reflex returns in approximately 53 minutes, followed by sternal recumbency a
further 35 minutes later and standing a further 36 minutes later.
CAT
For analgesia
Pre-operative:
RouteDose
Butorphanol
mg/kg body
weight
Dose
Alvegesic
vet. 10 mg/ml
ml/kg body
weight
CommentIM or
SC
0.40.04 mlAdminister 15-30 minutes prior to the
administration of IV induction
anaesthetic agents
Administer 5 minutes before induction
with IM induction anaesthetic agents
such as combinations of IM
acepromazine/ ketamine or
xylazine/ketamine
Preclinical model studies and clinical field trials in cats demonstrated that the
analgesic effect of butorphanol tartrate is seen within 20 minutes.
Post-operative
RouteDose
Butorphanol
mg/kg body
weight
Dose
Alvegesic
vet. 10 mg/ml
ml/kg body
weight
CommentSC or
IM
0.40 04 mlAdminister 15 minutes before recoveryIV0.10.01 mlAdminister 15 minutes before recovery
For sedation when used in combination with other drugs
RouteDose
Butorphanol
mg/kg body
weight
Dose
Alvegesic vet
10 mg/ml
ml/kg body
weight
Dose
Medetomidine
hydrochloride
mg/kg body
weight
CommentIM or0.40.04 ml0.05Local anaestheticSCinfiltration should beused for woundsuturing
For anaesthesia in combination with medetomidine & ketamine
RouteDose
Butorphanol
mg/kg
body weight
Dose
Alvegesic
vet 10
mg/ml
ml/kg
body
weight
Dose
Medetomidine
mg/kg
body weight
Dose
Ketamine
mg/kg
body weight
CommentsIM0.400.04 ml0.085.0*Recumbency and
loss of pedal reflex
occurs within 2-3
minutes and 3
minutes,
respectively, post
injection.
Reversal with
atipamezole results
in return of the pedal
reflex 2 minutes
later, sternal
recumbency 6
minutes later and
standing 31 minutes
later.
IV0.100.01 ml0.041.25-2.50
(depending
on depth of
anaesthesia
required)
Reversal with
atipamezole results
in return of the pedal
reflex 4 minutes
later, sternal
recumbency 7
minutes later and
standing 18 minutes
later.
* Ketamine should be administered 15 minutes after IM administration
of the butorphanol/medetomidine combination.
possible.
HORSE
For analgesia
Analgesic effects are seen within 15 minutes of injection and last approximately 2
hours.
RouteDose
Butorphanol
mg/kg body
weight
Dose Alvegesic
vet. 10 mg/ml
ml/kg body
weight
CommentIV0.100.01 mlDose may be repeated after 3-4
hours. Treatment should not exceed
48 hours.
For sedation (intravenous use) when used in combination with other drugs
Combination sedation
agent
(given 5 minutes
before Alvegesic vet.
10mg/ml Solution for
Injection)
IV Dose of
Combination
Agent
mg/kg body
weight
IV Dose
Butorphanol
mg/kg body
weight
IV Dose
Alvegesic vet.
10mg/ml
ml/100 kg body
weight
Detomidine
hydrochloride*
0.0120.0250.25 ml / 100 kg bwRomfidine0.04-0.120.020.20 ml / 100 kg bw
* Clinical experience has shown that a total dose rate of 5 mg detomidine
hydrochloride and 10 mg butorphanol affords effective, safe sedation in horses above
200 kg body weight.
DOG
For analgesia
Analgesic effects are seen within 15 minutes post injection.
RouteDose
Butorphanol
mg/kg body
weight
Dose Alvegesic vet.
10 mg/ml
ml/kg body weight
CommentIV,
IM or
SC
0.20-0.300.02-0.03 mlAvoid rapid IV injection (see
section 3.6). Administer 15
minutes before terminating
anaesthesia to provide
analgesia in the recovery phase.
Repeat dose as required.
For sedation when used in combination with other drugs
RouteDose
Butorphanol
mg/kg
body
weight
Dose
Alvegesic
vet
10 mg/ml
ml/kg
body
weight
Dose
Medetomidine
hydrochloride
mg/kg
body weight
CommentIM or0.10.01 ml0.01-0.025Allow 20 minutes for profoundIV(depends onsedation to develop beforedegree ofcommencing the proceduresedationrequired)
For use as a premedicant/pre-anaesthetic
1. when Alvegesic vet 10mg/ml Solution for Injection is used as the sole agent:
Dose
Butorphanol
mg/kg body
weight
Dose
Alvegesic vet 10
mg/ml
ml/kg body
weight
RouteTime of administration0.1-0.200.01-0.02 mlIV, IM or
SC
15 minutes prior to induction
2. when Alvegesic vet 10mg/ml Solution for Injection is used together with 0.02
mg/kg acepromazine:
Dose
Butorphanol
mg/kg body
weight
Dose
Alvegesic vet 10
mg/ml
ml/kg body weight
RouteTime of administration0.10*0.01 ml*IV or IMAllow at least 20 minutes before
the onset of action but the time
between pre-medication and
induction is flexible from 20-120
minutes
The dose may be increased to 0.2 mg/kg (equivalent to 0.02 ml/kg) if the animal
is already experiencing pain before the procedure commences or if a higher
plane of analgesia is required during surgery.
For anaesthesia in combination with medetomidine & ketamine
RouteDose
Butorphanol
mg/kg
body weight
Dose
Alvegesic
vet 10
mg/ml
ml/kg
body
weight
Dose
Medetomidine
mg/kg
body weight
Dose
Ketamine
mg/kg
body
weight
CommentsIM0.100.01 ml0.0255.0*Reversal with
atipamezole is not
recommended
* Ketamine should be administered 15 minutes after IM administration
of the butorphanol/medetomidine combination.
Post IM administration of the combination the veterinary medicinal product
/medetomidine, recumbency and loss of pedal reflex occurs in approximately 6
minutes and 14 minutes, respectively. Post administration of ketamine, the pedal
reflex returns in approximately 53 minutes, followed by sternal recumbency a
further 35 minutes later and standing a further 36 minutes later.
CAT
For analgesia
Pre-operative:
RouteDose
Butorphanol
mg/kg body
weight
Dose
Alvegesic
vet. 10 mg/ml
ml/kg body
weight
CommentIM or
SC
0.40.04 mlAdminister 15-30 minutes prior to the
administration of IV induction
anaesthetic agents
Administer 5 minutes before induction
with IM induction anaesthetic agents
such as combinations of IM
acepromazine/ ketamine or
xylazine/ketamine
Preclinical model studies and clinical field trials in cats demonstrated that the
analgesic effect of butorphanol tartrate is seen within 20 minutes.
Post-operative
RouteDose
Butorphanol
mg/kg body
weight
Dose
Alvegesic
vet. 10 mg/ml
ml/kg body
weight
CommentSC or
IM
0.40 04 mlAdminister 15 minutes before recoveryIV0.10.01 mlAdminister 15 minutes before recovery
For sedation when used in combination with other drugs
RouteDose
Butorphanol
mg/kg body
weight
Dose
Alvegesic vet
10 mg/ml
ml/kg body
weight
Dose
Medetomidine
hydrochloride
mg/kg body
weight
CommentIM or0.40.04 ml0.05Local anaestheticSCinfiltration should beused for woundsuturing
For anaesthesia in combination with medetomidine & ketamine
RouteDose
Butorphanol
mg/kg
body weight
Dose
Alvegesic
vet 10
mg/ml
ml/kg
body
weight
Dose
Medetomidine
mg/kg
body weight
Dose
Ketamine
mg/kg
body weight
CommentsIM0.400.04 ml0.085.0*Recumbency and
loss of pedal reflex
occurs within 2-3
minutes and 3
minutes,
respectively, post
injection.
Reversal with
atipamezole results
in return of the pedal
reflex 2 minutes
later, sternal
recumbency 6
minutes later and
standing 31 minutes
later.
IV0.100.01 ml0.041.25-2.50
(depending
on depth of
anaesthesia
required)
Reversal with
atipamezole results
in return of the pedal
reflex 4 minutes
later, sternal
recumbency 7
minutes later and
standing 18 minutes
later.
* Ketamine should be administered 15 minutes after IM administration
of the butorphanol/medetomidine combination.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals with severe dysfunction of the liver or kidneys.
Use of butorphanol is contraindicated in case of cerebral injury or organic brain
lesions and in animals with obstructive respiratory disease, heart dysfunction or
spastic conditions.
Horse:
Butorphanol/Detomidine hydrochloride combination:
Do not use in pregnant animals.
Do not use in horses with pre-existing cardiac dysrhythmia or bradycardia.
The combination will cause a reduction in gastrointestinal motility and consequently
should not be used in cases of colic associated with impaction.
Due to a possible depressive effect on the respiratory system, the veterinary
medicinal product is contraindicated for use in horses with emphysema.
Butorphanol/Romifidine combination:
The combination should not be used during the last month of pregnancy.
excipients.
Do not use in animals with severe dysfunction of the liver or kidneys.
Use of butorphanol is contraindicated in case of cerebral injury or organic brain
lesions and in animals with obstructive respiratory disease, heart dysfunction or
spastic conditions.
Horse:
Butorphanol/Detomidine hydrochloride combination:
Do not use in pregnant animals.
Do not use in horses with pre-existing cardiac dysrhythmia or bradycardia.
The combination will cause a reduction in gastrointestinal motility and consequently
should not be used in cases of colic associated with impaction.
Due to a possible depressive effect on the respiratory system, the veterinary
medicinal product is contraindicated for use in horses with emphysema.
Butorphanol/Romifidine combination:
The combination should not be used during the last month of pregnancy.
Horses:
Very common
(>1 animal / 10 animals treated):
Ataxia
1,2
, Sedation
Undetermined frequency
(cannot be estimated from available data):
Pacing
, Restlessness
Cardiac depression
Digestive tract disorder
Shivering
Respiratory depression
Mild, may persist for 3 -10 minutes, may last 1-2 hours in some cases.
Mild to severe, may be encountered in combination with detomidine, but clinical
studies have shown that horses are unlikely to collapse. Normal precautions should
be observed to prevent self-injury.
may occur in about 15% of horses.
Excitatory locomotor effects after IV bolus injection at the maximum recommended
dose (0.1 mg/kg body weight).
No reduction in gastrointestinal transit time is seen. These effects are dose
dependent and are generally minor and transient.
Dogs:
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea, Ataxia
, AnorexiaUndetermined frequency
(cannot be estimated from available data):
Injection site pain
Cardiac depression
3,4
Digestive tract disorder
Sedation
Respiratory depression
3,4
Transient clinical sign.
Localised pain following intramuscular injection.
As evidenced by a decrease in respiratory rate, development of bradycardia (slow
heart rate) and a decrease in diastolic pressure may occur. The degree of depression
is dose dependent. The extent of depression is dose dependent. Naloxone may be
used as an antidote.
Moderate to severe cardiopulmonary depression may occur during rapid
intravenous injection.
Reduction in gastrointestinal motility.
Mild intensity.
Cats:
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea, Ataxia, AnorexiaUndetermined frequency
(cannot be estimated from available data):
Injection site pain
Agitation
Mydriasis, Sedation
Respiratory depression
Dysphoria
Localised pain following intramuscular injection.
Mild intensity
Naloxone may be used as an antidote
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Very common
(>1 animal / 10 animals treated):
Ataxia
1,2
, Sedation
Undetermined frequency
(cannot be estimated from available data):
Pacing
, Restlessness
Cardiac depression
Digestive tract disorder
Shivering
Respiratory depression
Mild, may persist for 3 -10 minutes, may last 1-2 hours in some cases.
Mild to severe, may be encountered in combination with detomidine, but clinical
studies have shown that horses are unlikely to collapse. Normal precautions should
be observed to prevent self-injury.
may occur in about 15% of horses.
Excitatory locomotor effects after IV bolus injection at the maximum recommended
dose (0.1 mg/kg body weight).
No reduction in gastrointestinal transit time is seen. These effects are dose
dependent and are generally minor and transient.
Dogs:
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea, Ataxia
, AnorexiaUndetermined frequency
(cannot be estimated from available data):
Injection site pain
Cardiac depression
3,4
Digestive tract disorder
Sedation
Respiratory depression
3,4
Transient clinical sign.
Localised pain following intramuscular injection.
As evidenced by a decrease in respiratory rate, development of bradycardia (slow
heart rate) and a decrease in diastolic pressure may occur. The degree of depression
is dose dependent. The extent of depression is dose dependent. Naloxone may be
used as an antidote.
Moderate to severe cardiopulmonary depression may occur during rapid
intravenous injection.
Reduction in gastrointestinal motility.
Mild intensity.
Cats:
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea, Ataxia, AnorexiaUndetermined frequency
(cannot be estimated from available data):
Injection site pain
Agitation
Mydriasis, Sedation
Respiratory depression
Dysphoria
Localised pain following intramuscular injection.
Mild intensity
Naloxone may be used as an antidote
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Butorphanol is intended for use where short duration analgesia (horse, dog) or short
to medium duration analgesia (cat) is required.
Marked sedation does not occur in cats when butorphanol is used as a sole agent.
In cats, individual response to butorphanol may be variable. In the absence of an
adequate analgesic response, an alternative analgesic agent should be used.
In cats increasing of the dose will not increase intensity or duration of desired effects.
Special precautions for safe use in the target species:
Before using any combinations consult the contraindications and warnings that
appear on the other veterinary medicinal product’s Summary of Product
Characteristics or data sheets.
Due to its antitussive properties, butorphanol may lead to an accumulation of mucous
in the respiratory tract. Therefore, in animals with respiratory diseases associated
with increased mucous production or in animals that are being treated with
expectorants, butorphanol should only be used on the basis of a risk-benefit analysis
by the responsible veterinarian.
For the concomitant use of other central nervous depressants refer to section 3.8.
For the combination of butorphanol and α2-adrenoceptor agonists refer to section
3.8. Special care should be taken when administering the veterinary medicinal
product to animals with impaired liver or kidney function.
FOR ALL TARGET SPECIES
The safety of the veterinary medicinal product in puppies, kitten and foals has not
been established. Use of the product in these groups should be on the basis of a
benefit/risk analysis by the responsible veterinarian.
Horse:
- The use of the veterinary medicinal product at the recommended dose may lead to
transient ataxia
and/or excitement.
-Therefore, to prevent injuries in patient and people when treating horses, the
location for the treatment should be chosen carefully.
Dog:
- When administering as an intravenous injection, do not inject as a bolus.
- When administered as an intravenous injection, the veterinary medicinal product
must be injected slowly.
Do not inject as a bolus.
The dose must be reduced by 25-50% for dogs with MDR1 mutation.
Cat:
-When administered as an intravenous injection, the veterinary medicinal product
must be injected slowly. Use of either insulin syringes or 1 ml graduated syringes is
recommended.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Butorphanol has opioid activity. Precautions should be taken to avoid accidental
injection / self-injection with this potent drug. The most frequent adverse effects of
butorphanol in humans are drowsiness, sweating, nausea, dizziness and vertigo and
may occur following unintended self-injection. In case of accidental self-injection,
seek medical advice immediately and show the package leaflet or the label to the
physician.
DO NOT DRIVE. Effects can be reversed with an opioid (e.g. naloxone). antagonist.
Wash splashes from skin and eyes immediately.
Special precautions for the protection of the environment:
Not applicable.
to medium duration analgesia (cat) is required.
Marked sedation does not occur in cats when butorphanol is used as a sole agent.
In cats, individual response to butorphanol may be variable. In the absence of an
adequate analgesic response, an alternative analgesic agent should be used.
In cats increasing of the dose will not increase intensity or duration of desired effects.
Special precautions for safe use in the target species:
Before using any combinations consult the contraindications and warnings that
appear on the other veterinary medicinal product’s Summary of Product
Characteristics or data sheets.
Due to its antitussive properties, butorphanol may lead to an accumulation of mucous
in the respiratory tract. Therefore, in animals with respiratory diseases associated
with increased mucous production or in animals that are being treated with
expectorants, butorphanol should only be used on the basis of a risk-benefit analysis
by the responsible veterinarian.
For the concomitant use of other central nervous depressants refer to section 3.8.
For the combination of butorphanol and α2-adrenoceptor agonists refer to section
3.8. Special care should be taken when administering the veterinary medicinal
product to animals with impaired liver or kidney function.
FOR ALL TARGET SPECIES
The safety of the veterinary medicinal product in puppies, kitten and foals has not
been established. Use of the product in these groups should be on the basis of a
benefit/risk analysis by the responsible veterinarian.
Horse:
- The use of the veterinary medicinal product at the recommended dose may lead to
transient ataxia
and/or excitement.
-Therefore, to prevent injuries in patient and people when treating horses, the
location for the treatment should be chosen carefully.
Dog:
- When administering as an intravenous injection, do not inject as a bolus.
- When administered as an intravenous injection, the veterinary medicinal product
must be injected slowly.
Do not inject as a bolus.
The dose must be reduced by 25-50% for dogs with MDR1 mutation.
Cat:
-When administered as an intravenous injection, the veterinary medicinal product
must be injected slowly. Use of either insulin syringes or 1 ml graduated syringes is
recommended.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Butorphanol has opioid activity. Precautions should be taken to avoid accidental
injection / self-injection with this potent drug. The most frequent adverse effects of
butorphanol in humans are drowsiness, sweating, nausea, dizziness and vertigo and
may occur following unintended self-injection. In case of accidental self-injection,
seek medical advice immediately and show the package leaflet or the label to the
physician.
DO NOT DRIVE. Effects can be reversed with an opioid (e.g. naloxone). antagonist.
Wash splashes from skin and eyes immediately.
Special precautions for the protection of the environment:
Not applicable.
Butorphanol must be used with caution when used in combination with other
sedatives or analgesics (see section 3.5). Reduce appropriately dosages of both
butorphanol and alpha-agonists to avoid any adverse synergistic effect. Use of
butorphanol may influence subsequent administration of other analgesics e.g. higher
doses of pure agonist opioid analgesics such as morphine or oxymorphone may be
necessary.
Because of its antagonist properties at the opiate µ-opioid receptor, butorphanol may
remove the analgesic effect in animals which have already received pure µ-opioid
agonists.
The concomitant use of other central nervous depressants would be expected to
potentiate the effects of butorphanol and such drugs should be used with caution. A
reduced dose should be used when administering these agents concurrently.
The combination of butorphanol and α2-adrenoceptor agonists should be used with
caution in animals with cardiovascular disease. The concurrent use of anticholinergic
drugs, e.g atropine should be considered.
sedatives or analgesics (see section 3.5). Reduce appropriately dosages of both
butorphanol and alpha-agonists to avoid any adverse synergistic effect. Use of
butorphanol may influence subsequent administration of other analgesics e.g. higher
doses of pure agonist opioid analgesics such as morphine or oxymorphone may be
necessary.
Because of its antagonist properties at the opiate µ-opioid receptor, butorphanol may
remove the analgesic effect in animals which have already received pure µ-opioid
agonists.
The concomitant use of other central nervous depressants would be expected to
potentiate the effects of butorphanol and such drugs should be used with caution. A
reduced dose should be used when administering these agents concurrently.
The combination of butorphanol and α2-adrenoceptor agonists should be used with
caution in animals with cardiovascular disease. The concurrent use of anticholinergic
drugs, e.g atropine should be considered.
Keep the vial in the outer carton in order to protect from light. Do not refrigerate or
freeze.
freeze.
Horse:Meat and offal: Zero days.
Milk: Zero hours.
Milk: Zero hours.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Butorphanol
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VV.M.D. n.v.
injection
Cats
Dogs
Horses
Butador 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VVetViva Richter GmbH
injection
Cats
Dogs
Horses
Butador 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VVetViva Richter GmbH
injection
Cats
Dogs
Horses
ButorVet 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VC&H Generics Ltd
injection
Cats
Dogs
Horses
ButorVet 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VC&H Generics Ltd
injection
Cats
Dogs
Horses
Dolorex 10 mg/ml Solution for Injection for Horse, Dog and Cat
POM-VMSD Animal Health UK Limited
injection
Cats
Dogs
Horses
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in painkiller
Related Medications
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
injection
Rx
Cats
Dogs
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.